Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Meta Expands AI Training With Employee Activity Tracking Tools 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SAN DIEGO, March 07, 2016 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the 28th Annual Roth Conference at 3:30 pm PST on Monday, March 14, 2016, at the Ritz Carlton in Dana Point, CA.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The company’s clinical-stage pipeline includes two product candidates: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers and wet AMD through a collaboration with Santen Pharmaceutical Company Ltd., and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
